Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE...
July 07, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
June 25, 2026 22:00 ET | Source: Bitdeer AI

Bitdeer AI Wins “AI Cloud Platform of the Year” in 2026 AI Breakthrough Awards, Recognized as a Global Leader in AI Cloud Infrastructure

SINGAPORE, June 26, 2026 (GLOBE NEWSWIRE) -- Bitdeer AI, part of Bitdeer Technologies Group (NASDAQ: BTDR) and a preferred NVIDIA Cloud Partner, today announced it has been the winner of “AI Cloud...
May 27, 2026 16:01 ET | Source: Nutanix, Inc.

Nutanix Reports Third Quarter Fiscal 2026 Financial Results

Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced financial results for its third quarter ended April 30, 2026.
May 19, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the broader ophthalmology community at ASCRS...
April 29, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO...
March 18, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
February 10, 2026 08:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
January 30, 2026 11:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
January 28, 2026 07:40 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Successful Type C Meeting with the FDA

LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...